The ALS Data I Can't Stop Thinking About
ALS usually leads to a one-point decline per month — and a six-point slide is the difference between a weak arm and not being able to climb stairs. So what happens when a drug shows little to no progression at six months? In this episode of The Upside, Lou Basenese sits down with Coya Therapeutics (COYA) CEO Arun Swaminathan to break down the ALS data behind the small study for COYA 302 and the upcoming Phase 2 readout, the $700M licensing deal with Dr. Reddy's (RDY) and its new ~10% stake, Fast Track designation, the frontal temporal dementia (FTD) trial starting later this year, and why Aru…
